# Fathom Therapeutics

> Fathom Therapeutics (formerly Atommap) is a New York and Boston based biotech building Microcosmos, a drug-design engine that fuses quantum chemistry and AI to simulate how proteins actually move inside living cells. By modeling motion instead of static snapshots - reportedly up to 10,000x faster than conventional simulation - the company hunts for the fleeting binding pockets that make 'undruggable' targets druggable, then designs small molecules, degraders, and molecular glues against them. In April 2026 it raised a $47M oversubscribed Series A led by Sutter Hill Ventures.

- **Founded:** 2021
- **Headquarters:** New York, New York, United States (second office in Boston)
- **Founders:** Huafeng Xu (Co-Founder & CEO (pioneer behind the Anton supercomputer for molecular dynamics)), Yujie Wu (Co-Founder & Chief Technology Officer (formerly Roivant Discovery, Schrodinger)), Jesus Izaguirre (Co-Founder & Chief Computational Scientist (formerly Roivant Discovery, Silicon Therapeutics))
- **Team size:** ~22 employees
- **Products:** Microcosmos, Lab-in-the-loop platform, Internal discovery pipeline
- **Notable:** Raised $47M oversubscribed Series A in April 2026 led by Sutter Hill Ventures, Founding/leadership team collectively advanced 19 drugs into the clinic, including 7 FDA-approved medicines, Reported designing potent degraders for a previously 'undruggable' target within six weeks

## Products & services

- **Microcosmos** — Proprietary drug-design engine combining quantum chemistry and AI to simulate protein motion at atomic resolution, reportedly accelerating protein-dynamics modeling by up to 10,000x while preserving accuracy. It reveals transient binding sites invisible to static models and supports generative molecule design.
- **Lab-in-the-loop platform** — Tight cycles between computational prediction and wet-lab experimental validation, enabling rapid iterative refinement of drug candidates.
- **Internal discovery pipeline** — Programs targeting high-impact diseases, including protein degraders and molecular glues for historically intractable targets; lead program reported to be in animal efficacy studies.

## Achievements

- Raised $47M oversubscribed Series A in April 2026 led by Sutter Hill Ventures
- Founding/leadership team collectively advanced 19 drugs into the clinic, including 7 FDA-approved medicines
- Reported designing potent degraders for a previously 'undruggable' target within six weeks
- Lead program reported to be in animal efficacy studies
- Microcosmos platform reported to accelerate protein-dynamics modeling by up to 10,000x

## Latest updates

- **2026-04** — Rebranded from Atommap to Fathom Therapeutics and announced a $47M oversubscribed Series A led by Sutter Hill Ventures.
- **2026-04** — Named Mandana Honu, PhD as Chief Business Officer and added Diala Ezzeddine, PhD to the board.

## Links

- Website: https://www.fathomtx.com/
- LinkedIn: https://www.linkedin.com/company/fathomtx/
- Bluesky: https://bsky.app/profile/fathomtx.bsky.social

---

Profile page: https://yespress.io/fathom-therapeutics
Published by YesPress — https://yespress.io
Last updated: 2026-06-07